Solid Biosciences Announces Closing Of Acquisition Of Aavantibio And Concurrent $75 Million Private Placement
Acquiring Company
Solid Biosciences
Acquired Company
AavantiBio, Inc.
MassachusettsGainesvilleBiotechnologyHealthcareHealth CareGeneticsTherapeuticsBiotechnologyHealth CareGeneticsTherapeuticsDescription
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its acquisition of AavantiBio, a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies, including its pipeline assets and net cash. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreich’s ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Bo Cumbo, the Chief Executive Officer of AavantiBio, will assume the role of President and CEO of Solid Biosciences.
Fundz sees it the moment Solid Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired AavantiBio, Inc.?
AavantiBio, Inc. was acquired by Solid Biosciences, based in Massachusetts. The deal was reported on December 5, 2022. Solid Biosciences is publicly traded (SLDB) and operates in Biotechnology.
When did Solid Biosciences acquire AavantiBio, Inc.?
Solid Biosciences's acquisition of AavantiBio, Inc. was reported on December 5, 2022. Solid Biosciences Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AavantiBio, Inc. do?
It is privately held, operating in Biotechnology, and is based in Gainesville.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.